The estimated Net Worth of Carol R. Lizak is at least $1.18 ezer dollars as of 17 May 2024. Ms. Lizak owns over 431 units of Jaguar Health Inc stock worth over $1,177 and over the last 5 years she sold JAGX stock worth over $0. In addition, she makes $0 as Senior Vice President - Finance és Chief Accounting Officer at Jaguar Health Inc.
Carol has made over 6 trades of the Jaguar Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 431 units of JAGX stock worth $487 on 17 May 2024.
The largest trade she's ever made was buying 7,968 units of Jaguar Health Inc stock on 13 September 2021 worth over $20,000. On average, Carol trades about 1,346 units every 98 days since 2020. As of 17 May 2024 she still owns at least 1,042 units of Jaguar Health Inc stock.
You can see the complete history of Ms. Lizak stock trades at the bottom of the page.
Carol R. Lizak serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. She served as our Vice President of Finance and Corporate Controller from May 2019 to August 2019. Prior to joining us, Ms. Lizak served as Senior Director and Corporate Controller of Zosano Pharma Corporation from November 2017 to January 2019, as Controller of Quantum Secure, Inc. from July 2016 to August 2017, and as Executive Director, Corporate Controller of Alexza Pharmaceuticals, Inc. from September 2014 to July 2016. Prior thereto, she spent nine years as Corporate Controller of a subsidiary of HID Global Corporation. Ms. Lizak holds an M.B.A from Pepperdine University, Graziadio School of Business and Management and a B.S. in Business Administration from the University of Santo Tomas.
Carol Lizak is 56, she's been the Senior Vice President - Finance és Chief Accounting Officer of Jaguar Health Inc since 2020. There are 11 older and 3 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
Carol's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 10 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski és Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: